Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at Int'l Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies
13th Nov 2006, 16:40 GMT
Altus Pharmaceuticals, a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with GI and metabolic disorders, announced the presentation of results from its Phase II study of its product candidate ALTU-238 at The 3rd Int'l Congress of the Growth Hormone Research Society and the Insulin-like Growth Factor Research Society, which is taking place this week in Kobe, Japan.
Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at Int'l Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies related news:
- - Webcast Alert: Isis Pharmaceuticals Announces Its Analyst/Investor Webcast Presentation — Partnerships/ Joint Ventures News from StratCenter.com
- Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress of the Societe Internationale d'Urologie — PR Newswire: All Releases
- 1st Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement of Initiation of Phase II Trial in Advanced Carcinoid Cancer Patients — Pharmaceuticals News from StratCenter.com
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting — Market Wire - Pharmaceuticals and Biotech
- Isis Pharma's shares soar on cholesterol-drug Phase II data — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Aeterna prostate cancer drug shows promise — Pharmaceutical Business Review Latest News
- NovaCardia Presents Phase II Data for KW-3902 at American Heart Assoc's 79th Annual Scientific Sessions — Nephrology/ Dialysis News from StratCenter.com
- Neurogen Announces Phase I Clinical Trial For Proprietary Obesity Drug — Health News from Medical News Today
- Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting — Partnerships/ Joint Ventures News from StratCenter.com
- Growth Factor Signals Influence Balance Between Normal Growth And Cancerous Growth — Health News from Medical News Today
Latest news from Nephrology/ Dialysis News from StratCenter.com:
- New Data Show ACTOS Halted Progression of Atherosclerosis as Indicated by CIMT in Patients with Type 2 Diabetes
- Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study
- Aksys Reports Q3 2006 Financial Results
- Opexa Reports Q3 Financial Results
- Treatment of Diabetic Foot Ulcers Addressed at Upcoming American Heart Assoc Meeting
- Weight Loss Surgery Assists in Eliminating, Avoiding Type 2 Diabetes; American Institute of Gastric Banding Recognizes November as Nat'l Diabetes Month
- Federal Economic Development Agency Enlists Support of African-American Churches in the IL Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the MS Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the LA Delta
- Spherix Reports Q3 Earnings